[ad_1] Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of YESINTEK (ustekinumab-kfce), a biosimilar to Stelara (ustekinumab). This makes YESINTEK one of the first biosimilar alternatives to enter the US market for the blockbuster immunology drug. Company Value Change %Change YESINTEK is approved for the […]
US FDA approves Biocon Biologics’ YESINTEK for autoimmune diseases – CNBC TV18
[ad_1] Biocon Biologics has announced that the US Food and Drug Administration (FDA) has approved YESINTEK, a monoclonal antibody for the treatment of autoimmune conditions, including Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. YESINTEK works by targeting specific proteins that contribute to inflammation, offering a new treatment option for patients with these chronic […]